Physician profile
Robert A Levine
NPI 1275620445
$1,577.74
in general payments reported to CMS, 2019-2025
10 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $48.00 · 2021: $181 · 2022: $74.81 · 2023: $21.47 · 2024: $56.00 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $920 · Food and Beverage: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $920.00 |
| Food and Beverage | $354.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visionary Optics LLC | $920.00 | 2025 | |
| Bausch & Lomb Americas INC. | $275.96 | 2022-2025 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $122.51 | 2021-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $84.81 | 2020-2021 | |
| Glaukos Corporation | $70.13 | 2021 | |
| Allergan, INC. | $26.93 | 2022 | |
| Alcon Vision LLC | $21.85 | 2025 | Precision7 |
| Biotissue Holdings INC. | $21.09 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $17.36 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.